De­vel­op­ing a Sanofi cast-off, Im­pact Bio­med­i­cines now sub­ject of $7B Cel­gene ac­qui­si­tion deal

A start­up de­vel­op­ing the once-dis­card­ed fe­dra­tinib, a drug cast off from Sanofi due to safe­ty con­cerns back in 2013, is now the sub­ject of a $7 bil­lion ac­qui­si­tion deal by Cel­gene.

The tiny San Diego com­pa­ny at the cen­ter of the deal is Im­pact Bio­med­i­cines, found­ed by John Hood, the ex-co-founder and CSO of re­gen­er­a­tive med­i­cines com­pa­ny Sa­mumed. Be­fore his stint at Sa­mumed, Hood had been the co-in­ven­tor of fe­dra­tinib while re­search chief at Targe­Gen. Then Sanofi scooped up the mid-stage JAK2 myelofi­bro­sis drug with big plans to make it the cen­ter­piece of their new­ly re­vived on­col­o­gy ef­fort and Hood went on to Sa­mumed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.